Alpine Immune Sciences Inc (ALPN)

$64.6

+0.01

(+0.02%)▲

Market is closed - opens 7 PM, 02 May 2024

Insights on Alpine Immune Sciences Inc

  • Increasing Revenue

    Revenue is up for the last 3 quarters, 8.59M → 30.85M (in $), with an average increase of 40.9% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 3 quarters, -13.15M → 5.96M (in $), with an average increase of 154.5% per quarter

Performance

  • $64.58
    $64.69
    $64.60
    downward going graph

    0.03%

    Downside

    Day's Volatility :0.17%

    Upside

    0.14%

    downward going graph
  • $6.71
    $64.72
    $64.60
    downward going graph

    89.61%

    Downside

    52 Weeks Volatility :89.63%

    Upside

    0.19%

    downward going graph

Returns

PeriodAlpine Immune Sciences IncIndex (Russel 2000)
3 Months
130.84%
0.0%
6 Months
513.97%
0.0%
1 Year
762.35%
0.0%
3 Years
396.85%
-21.9%

Highlights

Market Capitalization
4.2B
Book Value
$5.43
Earnings Per Share (EPS)
-0.64
PEG Ratio
0.0
Wall Street Target Price
61.5
Profit Margin
-54.66%
Operating Margin TTM
5.01%
Return On Assets TTM
-8.3%
Return On Equity TTM
-12.69%
Revenue TTM
58.9M
Revenue Per Share TTM
1.18
Quarterly Revenue Growth YOY
1011.4000000000001%
Gross Profit TTM
-40.2M
EBITDA
-43.7M
Diluted Eps TTM
-0.64
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.66
EPS Estimate Next Year
-1.89
EPS Estimate Current Quarter
-0.34
EPS Estimate Next Quarter
-0.36

Analyst Recommendation

Buy
    92%Buy
    7%Hold
    0
    0%Sell
Based on 14 Wall street analysts offering stock ratings for Alpine Immune Sciences Inc(by analysts ranked 0 to 5 stars)
Based on 14 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
13
11
11
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Downside of 4.8%

Current $64.60
Target $61.50

Company Financials

FY18Y/Y Change
Revenue
705.0K
↓ 59.27%
Net Income
-36.5M
↑ 368.8%
Net Profit Margin
-5.2K%
↓ 4725.84%
FY19Y/Y Change
Revenue
1.7M
↑ 146.81%
Net Income
-42.5M
↑ 16.57%
Net Profit Margin
-2.4K%
↑ 2730.98%
FY20Y/Y Change
Revenue
9.3M
↑ 436.49%
Net Income
-27.9M
↓ 34.31%
Net Profit Margin
-299.3%
↑ 2145.18%
FY21Y/Y Change
Revenue
23.4M
↑ 151.13%
Net Income
-50.3M
↑ 80.15%
Net Profit Margin
-214.7%
↑ 84.6%
FY22Y/Y Change
Revenue
30.1M
↑ 28.24%
Net Income
-57.8M
↑ 14.76%
Net Profit Margin
-192.13%
↑ 22.57%
FY23Y/Y Change
Revenue
58.9M
↑ 95.84%
Net Income
-32.2M
↓ 44.28%
Net Profit Margin
-54.66%
↑ 137.47%
Q3 FY22Q/Q Change
Revenue
8.4M
↑ 58.11%
Net Income
-12.7M
↓ 29.75%
Net Profit Margin
-151.95%
↑ 190.04%
Q4 FY22Q/Q Change
Revenue
2.8M
↓ 66.82%
Net Income
-18.9M
↑ 48.37%
Net Profit Margin
-679.54%
↓ 527.59%
Q1 FY23Q/Q Change
Revenue
9.4M
↑ 238.15%
Net Income
-11.0M
↓ 41.63%
Net Profit Margin
-117.29%
↑ 562.25%
Q2 FY23Q/Q Change
Revenue
8.6M
↓ 8.46%
Net Income
-13.2M
↑ 19.49%
Net Profit Margin
-153.1%
↓ 35.81%
Q3 FY23Q/Q Change
Revenue
10.0M
↑ 16.87%
Net Income
-11.7M
↓ 10.9%
Net Profit Margin
-116.72%
↑ 36.38%
Q4 FY23Q/Q Change
Revenue
30.9M
↑ 207.21%
Net Income
6.0M
↓ 150.84%
Net Profit Margin
19.32%
↑ 136.04%
FY18Y/Y Change
Total Assets
54.9M
↓ 35.61%
Total Liabilities
10.3M
↑ 63.08%
FY19Y/Y Change
Total Assets
54.1M
↓ 1.42%
Total Liabilities
24.6M
↑ 139.44%
FY20Y/Y Change
Total Assets
144.1M
↑ 166.37%
Total Liabilities
81.9M
↑ 232.8%
FY21Y/Y Change
Total Assets
255.9M
↑ 77.6%
Total Liabilities
135.0M
↑ 64.77%
FY22Y/Y Change
Total Assets
286.7M
↑ 12.03%
Total Liabilities
107.3M
↓ 20.54%
FY23Y/Y Change
Total Assets
381.8M
↑ 33.18%
Total Liabilities
53.9M
↓ 49.78%
Q3 FY22Q/Q Change
Total Assets
291.6M
↑ 35.11%
Total Liabilities
109.6M
↓ 5.76%
Q4 FY22Q/Q Change
Total Assets
286.7M
↓ 1.68%
Total Liabilities
107.3M
↓ 2.12%
Q1 FY23Q/Q Change
Total Assets
262.1M
↓ 8.58%
Total Liabilities
92.6M
↓ 13.71%
Q2 FY23Q/Q Change
Total Assets
252.8M
↓ 3.53%
Total Liabilities
83.4M
↓ 9.84%
Q3 FY23Q/Q Change
Total Assets
240.5M
↓ 4.86%
Total Liabilities
78.9M
↓ 5.43%
Q4 FY23Q/Q Change
Total Assets
381.8M
↑ 58.73%
Total Liabilities
53.9M
↓ 31.74%
FY18Y/Y Change
Operating Cash Flow
-28.4M
↑ 71.47%
Investing Cash Flow
32.1M
↓ 207.77%
Financing Cash Flow
-991.0K
↓ 102.32%
FY19Y/Y Change
Operating Cash Flow
-35.3M
↑ 24.39%
Investing Cash Flow
16.8M
↓ 47.81%
Financing Cash Flow
24.3M
↓ 2547.53%
FY20Y/Y Change
Operating Cash Flow
30.1M
↓ 185.11%
Investing Cash Flow
-72.8M
↓ 534.4%
Financing Cash Flow
61.4M
↑ 153.07%
FY21Y/Y Change
Operating Cash Flow
-15.2M
↓ 150.68%
Investing Cash Flow
-52.5M
↓ 27.93%
Financing Cash Flow
100.8M
↑ 64.16%
FY22Y/Y Change
Operating Cash Flow
-43.8M
↑ 186.95%
Investing Cash Flow
-113.3M
↑ 115.98%
Financing Cash Flow
102.7M
↑ 1.91%
Q3 FY22Q/Q Change
Operating Cash Flow
-16.3M
↑ 1.74%
Investing Cash Flow
25.8M
↑ 292.9%
Financing Cash Flow
92.8M
↓ 9199.61%
Q4 FY22Q/Q Change
Operating Cash Flow
-16.8M
↑ 2.68%
Investing Cash Flow
-107.9M
↓ 518.38%
Financing Cash Flow
11.5M
↓ 87.56%
Q1 FY23Q/Q Change
Operating Cash Flow
-26.2M
↑ 55.8%
Investing Cash Flow
28.4M
↓ 126.27%
Financing Cash Flow
-1.1M
↓ 109.42%
Q2 FY23Q/Q Change
Operating Cash Flow
-18.1M
↓ 30.82%
Investing Cash Flow
29.3M
↑ 3.45%
Financing Cash Flow
8.4M
↓ 872.59%

Technicals Summary

Sell

Neutral

Buy

Alpine Immune Sciences Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Alpine Immune Sciences Inc
Alpine Immune Sciences Inc
60.59%
513.97%
762.35%
396.85%
910.01%
Moderna, Inc.
Moderna, Inc.
4.46%
44.76%
-17.31%
-40.7%
317.84%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-8.11%
12.56%
10.41%
82.28%
161.35%
Novo Nordisk A/s
Novo Nordisk A/s
0.6%
31.36%
53.28%
240.62%
422.33%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-6.58%
6.36%
13.86%
80.23%
127.58%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Alpine Immune Sciences Inc
Alpine Immune Sciences Inc
NA
NA
0.0
-1.66
-0.13
-0.08
NA
5.43
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.22
-0.29
-0.12
NA
36.27
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
26.04
26.04
1.46
45.0
0.16
0.08
NA
242.47
Novo Nordisk A/s
Novo Nordisk A/s
47.43
47.43
2.4
3.35
0.88
0.23
0.01
23.9
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
28.81
28.81
0.53
16.75
0.23
0.13
NA
68.22
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Alpine Immune Sciences Inc
Alpine Immune Sciences Inc
Buy
$4.2B
910.01%
NA
-54.66%
Moderna, Inc.
Moderna, Inc.
Buy
$41.7B
317.84%
24.73
-68.84%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$99.5B
161.35%
26.04
30.14%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$562.8B
422.33%
47.43
36.03%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$103.6B
127.58%
28.81
36.68%

Institutional Holdings

  • Decheng Capital LLC

    10.81%

  • RA Capital Management, LLC

    7.49%

  • Great Point Partners LLC

    5.65%

  • Paradigm Biocapital Advisors LP

    4.85%

  • BlackRock Inc

    4.67%

  • Cormorant Asset Management, LLC

    3.89%

Company Information

founded in 2015 by a team responsible for the fda's approval of the world's first cancer immunotherapy and experts in the field of recombinant protein based immunotherapies, alpine immune sciences was created to capitalize on our unique understanding of immunology, modifying the complexities of the immune synapse for the benefit of patients living with cancer, autoimmune disorders, and other diseases. traded on nasdaq under ticker alpn.

Organization
Alpine Immune Sciences Inc
Employees
142
CEO
Dr. Mitchell H. Gold M.D.
Industry
Health Technology

Discover More

FAQs